January 1, 2024Open Access

Real-life experience of abrocitinib for the treatment of female patients with persistent erythema of rosacea

Key Points

Key points are not available for this paper at this time.

Abstract

Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.

Bookmark

View Full Paper

Cite This Study

Teng et al. (Mon,) studied this question.

synapsesocial.com/papers/69dbe45aeb8801008ea3c24d https://doi.org/https://doi.org/10.1177/1721727x241258794

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib2023 · 18 citations
2Tofacitinib for the Treatment of Steroid-Induced Rosacea2022 · 18 citations
3Improvement of Hailey–Hailey disease with abrocitinib2023 · 21 citations
4Updating the diagnosis, classification and assessment of rosacea: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel2016 · 280 citations
5Effect of abrocitinib in a patient with extensive necrobiosis lipoidica2023 · 11 citations

Bookmark

View Full Paper